Treatment of Relapsed Multiple Myeloma with Myelomatous Ascites Using Bispecific T-cell Engager (BiTE) Therapy

Wang C, Shyam KP, Kristi U, Hanona P, Huang J, Jaiyesimi I and Ezekwudo D

1Department of Hematology and Medical Oncology, Corewell Health William Beaumont University Hospital, USA 2Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, USA 3Department of Pathology, Corewell Health William Beaumont University Hospital, USA

^*Correspondance to: Shyam K Poudel 

 PDF  Full Text Case Report | Open Access

Abstract:

Myelomatous ascites is seen in less than 1% of multiple myeloma cases and associated with poor prognosis. This case report presents a 62-year-old male with relapsed MM who developed severe myelomatous ascites after autologous Hematopoietic Stem Cell Transplantation (HSCT). Upon initiation of Bispecific T-cell Engager (BiTE) therapy with talquetamab, the patient showed a rapid clinical improvement, including reduced ascites and a significant decrease in serum free lambda light chain levels within the first month. To our knowledge, this is the first report documenting the successful use of BiTE therapy for this rare complication.

Keywords:

Cite the Article:

Wang C, Shyam KP, Kristi U, Hanona P, Huang J, Jaiyesimi I, et al. Treatment of Relapsed Multiple Myeloma with Myelomatous Ascites Using Bispecific T-cell Engager (BiTE) Therapy. Ann Clin Case Rep. 2024; 9: 2671..